Raising the bar in liver cancer therapypharmaphorum interviews professor Jeff Evans, from the University of Glasgow’s Institute of Cancer Sciences, about findings of a Share XRaising the bar in liver cancer therapyhttps://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successGary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
Eisai angry over thyroid cancer drug impasse in EnglandThyroid cancer drug falls through gap in NHS funding Share XEisai angry over thyroid cancer drug impasse in Englandhttps://pharmaphorum.com/news/eisai-furious-england-blocks-cancer-drug-funding/